Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
05 Ottobre 2023 - 10:30PM
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company
will provide a corporate update and report financial results for
the third quarter ended September 30, 2023, on November 2, 2023.
The Company will host a conference call at 4:30 p.m. Eastern Time
on November 2, 2023.
The corporate update and financial results will
be provided via a press release after market close and will be
accessible under Press Releases in the Investors section of the Vir
website at www.vir.bio. Participants may access the conference call
via webcast on the Events & Presentations page of Vir’s website
at https://investors.vir.bio/events-presentations. A recorded
version of the call will be available on the website approximately
two hours after the completion of the event and will be archived
there for 30 days.
About Vir BiotechnologyVir
Biotechnology, Inc. is an immunology company focused on combining
cutting-edge technologies to treat and prevent infectious diseases
and other serious conditions. Vir has assembled two technology
platforms that are designed to stimulate and enhance the immune
system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis B and hepatitis delta
viruses, influenza A and B, human immunodeficiency virus and
COVID-19. Vir has several preclinical candidates in its pipeline,
including those targeting RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
Contacts:
Media
Carly Scaduto
Senior Director, Media Relations
cscaduto@vir.bio
+1 314-368-5189
Investors
Sasha Damouni Ellis
Executive Vice President, Chief Corporate Affairs Officer
sdamouni@vir.bio
Grafico Azioni Vir Biotechnology (NASDAQ:VIR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Vir Biotechnology (NASDAQ:VIR)
Storico
Da Giu 2023 a Giu 2024